tiprankstipranks
Trending News
More News >
Orthocell Ltd (AU:OCC)
ASX:OCC
Australian Market

Orthocell Ltd (OCC) AI Stock Analysis

Compare
51 Followers

Top Page

AU

Orthocell Ltd

(Sydney:OCC)

Rating:46Neutral
Price Target:
AU$1.00
▼(-20.00%Downside)
Orthocell Ltd's overall stock score is primarily driven by its financial performance challenges and weak valuation metrics. While the company shows revenue growth, persistent losses and significant cash flow issues weigh heavily on its stock score. Technical analysis further reinforces a cautious outlook with bearish momentum indicators. The lack of earnings call data and corporate events further limits positive influences on the score.

Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)

Orthocell Ltd Business Overview & Revenue Model

Company DescriptionOrthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
How the Company Makes MoneyOrthocell Ltd generates revenue primarily through the commercialization of its regenerative medicine products. The company earns money by selling its products, such as CelGro™ and Ortho-ATI®, to healthcare providers, including hospitals and clinics, which utilize these solutions for patients with soft tissue injuries. Additionally, Orthocell may engage in strategic partnerships and licensing agreements to enhance the distribution and adoption of its technologies, potentially leading to milestone payments and royalties. The company's revenue is influenced by the success of its clinical trials, regulatory approvals, and market adoption of its innovative solutions.

Orthocell Ltd Financial Statement Overview

Summary
Orthocell Ltd shows promising revenue growth, yet faces significant profitability challenges with consistent net losses. The balance sheet remains under pressure as equity decreases, though leverage is conservative. Cash flow management reflects volatility, highlighting operational cash flow issues despite adequate cash reserves. The company must address profitability to improve its financial health.
Income Statement
45
Neutral
Orthocell Ltd has shown consistent revenue growth, with a 25.3% increase in revenue from 2023 to 2024. However, the company has been struggling with negative profitability, as evidenced by a negative EBIT and net income across the years, reflecting challenges in achieving operational efficiency. The gross profit margin is relatively healthy at 69.38% in 2024, but the net profit margin remains negative at -135.1%, highlighting significant cost challenges.
Balance Sheet
55
Neutral
The company maintains a low debt-to-equity ratio of 0.15, indicating conservative leverage practices. However, stockholders' equity has decreased over the years, from $10.7M in 2019 to $4.5M in 2024, showing potential risks in financial stability. The equity ratio has also declined, suggesting a weakening financial position. Despite these concerns, the company has maintained a substantial cash position.
Cash Flow
50
Neutral
Orthocell Ltd experienced a significant drop in free cash flow, from $13.9M in 2023 to -$7.4M in 2024. The operating cash flow to net income ratio is negative, indicating cash flow challenges relative to net losses. Despite this, the company has historically shown strong cash positions and has managed financing activities effectively to support operations.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue6.31M5.32M4.24M1.53M1.02M719.52K
Gross Profit4.23M3.69M3.06M832.52K299.88K-6.40K
EBITDA-9.51M-11.68M-9.93M-11.52M-11.67M-9.25M
Net Income-3.25M-7.18M-6.25M-9.11M-9.04M-6.15M
Balance Sheet
Total Assets40.04M26.62M29.61M37.90M19.33M23.17M
Cash, Cash Equivalents and Short-Term Investments30.84M20.61M24.82M11.02M16.33M20.44M
Total Debt657.93K689.69K562.30K507.56K621.72K500.89K
Total Liabilities20.40M22.08M23.46M27.99M2.46M2.27M
Stockholders Equity19.64M4.53M6.15M9.90M16.87M20.90M
Cash Flow
Free Cash Flow-8.06M-7.45M13.96M-6.80M-4.82M-5.31M
Operating Cash Flow-7.34M-6.51M14.59M-6.26M-4.63M-5.26M
Investing Cash Flow-733.05K-942.02K-631.56K-535.02K-188.52K-55.20K
Financing Cash Flow19.29M3.24M-164.61K1.49M709.15K14.52M

Orthocell Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.25
Price Trends
50DMA
1.30
Negative
100DMA
1.37
Negative
200DMA
1.12
Positive
Market Momentum
MACD
-0.04
Negative
RSI
52.04
Neutral
STOCH
59.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OCC, the sentiment is Positive. The current price of 1.25 is above the 20-day moving average (MA) of 1.22, below the 50-day MA of 1.30, and above the 200-day MA of 1.12, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 52.04 is Neutral, neither overbought nor oversold. The STOCH value of 59.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:OCC.

Orthocell Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
48
Neutral
AU$2.43B4.28-64.25%2.88%36.51%13.13%
AUOCC
46
Neutral
AU$304.18M-29.77%6.07%59.09%
$81.49M-46.65%
$229.19M-31.16%
AUDXB
47
Neutral
AU$341.15M-524.68%322.26%-53.98%
AURCE
43
Neutral
AU$89.40M
-33.01%
AUALA
40
Underperform
AU$130.39M-85.35%315.11%51.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:OCC
Orthocell Ltd
1.25
0.89
247.22%
PBIGF
Paradigm Biopharmaceuticals
0.26
0.08
44.44%
PRRUF
Immutep Ltd
0.19
-0.01
-5.00%
AU:DXB
Dimerix Limited
0.57
0.04
7.55%
AU:RCE
Recce Pharmaceuticals Ltd.
0.31
-0.28
-47.46%
AU:ALA
Arovella Therapeutics Limited
0.11
-0.03
-21.43%

Orthocell Ltd Corporate Events

Orthocell Announces First US Surgery and Rollout of Remplir™
Jun 27, 2025

Orthocell Limited announced a webinar to discuss the first US surgical use of Remplir™ and the progress of its rollout in the US. This development marks a significant step in Orthocell’s expansion strategy, potentially enhancing its market position in regenerative medicine and offering new opportunities for stakeholders.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Marks Milestone with First US Use of Remplir™
Jun 26, 2025

Orthocell Limited has achieved a significant milestone with the first surgical use of its nerve repair product, Remplir™, in the United States, following FDA clearance. This marks a crucial step in penetrating the US$1.6 billion US nerve repair market, supported by a network of 14 specialist distributors. The successful surgery in Ohio highlights Orthocell’s commitment to expanding its market presence and driving sales growth, with expectations of increased revenue in the second half of 2025.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell’s Remplir Outperforms Standard Nerve Repair Techniques in New Study
Jun 18, 2025

Orthocell Limited has announced compelling interim results from a study demonstrating the superiority of its Remplir product over traditional suture-only nerve repair techniques. The study, which supports the company’s US sales rollout, shows that Remplir leads to better nerve regeneration and earlier muscle function recovery, reducing adverse tissue reactions associated with sutures. These findings are expected to drive rapid market adoption and redefine the nerve repair market, with Orthocell targeting a total addressable market of over $3.5 billion across selected jurisdictions.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Expands Market Presence with New Share Issuance
Jun 10, 2025

Orthocell Limited has issued 1,367,852 new shares following the exercise of unlisted options, allowing immediate trading under the Corporations Act exemption. This move is part of Orthocell’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its stakeholders by increasing liquidity and financial flexibility.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.28 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Ltd Announces Quotation of New Securities on ASX
Jun 10, 2025

Orthocell Ltd has announced the quotation of 1,367,852 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 10, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for further development and expansion of its regenerative medicine products.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.28 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

Orthocell Expands Remplir™ Sales to Hong Kong with New Regulatory Approval
May 12, 2025

Orthocell Limited has received regulatory approval to commence sales of its flagship nerve repair product, Remplir™, in Hong Kong, a strategically important market in the Asia Pacific region. This approval, granted ahead of schedule, adds to Orthocell’s growing portfolio of approvals in the US, Canada, Australia, New Zealand, Singapore, and Thailand, with further applications planned for the EU and UK. The company is leveraging external distributors to penetrate new markets while focusing internal resources on the US market. With a strong cash position and no debt, Orthocell is well-positioned to expand its commercial footprint and increase revenues.

Orthocell Expands US Distribution Network for Remplir™
May 8, 2025

Orthocell Ltd has rapidly expanded its US distribution network for its nerve repair product, Remplir™, appointing 12 distributors across 21 states, surpassing its initial target. This strategic expansion, following FDA clearance, is expected to significantly boost the company’s revenue and market penetration in the US$1.6 billion nerve repair market, leveraging experienced distributors and internal sales teams to drive growth.

Orthocell Gains Health Canada Approval for Nerve Repair Product Remplir
Apr 30, 2025

Orthocell Limited has received regulatory approval from Health Canada to sell its nerve repair product, Remplir™, in the Canadian market, which is valued at US$75 million. This approval expands the total addressable market for Remplir to US$1.8 billion, following recent approvals in the US and Thailand, and existing approvals in Australia, New Zealand, and Singapore. The company plans to appoint local distributors in Canada to drive sales, with first sales expected in the second half of 2025. Orthocell is well-funded with A$31.7 million in cash reserves, positioning it to capitalize on these new market opportunities and continue its global expansion strategy.

Orthocell Limited Requests Trading Halt for Pending Announcement
Apr 29, 2025

Orthocell Limited has requested a trading halt on its securities pending an announcement about a new regulatory approval for its product, Remplir. This move indicates a significant development that could impact the company’s market positioning and stakeholder interests, as regulatory approvals are crucial for product commercialization and market expansion.

Orthocell Limited Initiates Trading Halt Ahead of Major Announcement
Apr 29, 2025

Orthocell Limited has requested a trading halt on its securities pending an announcement about a new regulatory approval for its product, Remplir. This move indicates a significant development for the company, potentially impacting its market position and stakeholder interests as it awaits the formal announcement.

Orthocell Expands into Thai Market with Remplir™ Approval
Apr 28, 2025

Orthocell Ltd has received regulatory approval from the Thai FDA to commence sales of its nerve repair product Remplir™ in Thailand, a market valued at US$84 million. This approval, achieved through an expedited registration pathway, significantly enhances Orthocell’s presence in the Asia Pacific region and is expected to drive revenue growth. The company plans to partner with a local distributor and anticipates first sales in the second half of 2025. With a strong cash reserve and no debt, Orthocell is well-positioned to expand its global footprint and capitalize on the growing demand for nerve repair solutions.

Orthocell Expands into US Nerve Repair Market with New Distributors
Apr 23, 2025

Orthocell Limited has appointed its first four US distributors for its nerve repair product, Remplir™, following its recent FDA 510(k) clearance. This strategic move allows Orthocell to enter the US$1.6 billion US nerve repair market, with initial sales expected soon. The company plans to expand its distributor network to approximately 10 by mid-2025, covering around 25 states, to accelerate market penetration and revenue growth. Orthocell’s strong financial position and existing inventory support its US rollout, positioning it well for success in the competitive nerve repair industry.

Orthocell Secures FDA Clearance for Remplir™, Eyes US Market Expansion
Apr 14, 2025

Orthocell Limited has achieved a significant milestone with the US FDA 510(k) clearance for its nerve repair product, Remplir™, positioning the company to enter the lucrative US$1.6 billion nerve repair market. This clearance is expected to drive a substantial increase in revenue as the company has prepared logistics and sales pathways for its US launch. Additionally, Orthocell reported strong quarterly revenue growth, maintaining a robust cash position, and is expanding its market reach with regulatory applications in Canada and Thailand. The company’s inclusion in the S&P/ASX All Ordinaries Index further underscores its growing market presence.

Orthocell Gains ANVISA Approval for Striate+ in Brazil, Expanding Latin American Reach
Apr 9, 2025

Orthocell Limited has received regulatory approval from Brazil’s ANVISA for its dental regeneration product, Striate+, marking its first market authorization in Latin America. This approval is a strategic milestone for Orthocell, as Brazil represents a significant market opportunity and serves as a gateway for further expansion into Latin American countries. The approval follows the recent US FDA clearance for another product, Remplir, highlighting the company’s successful global commercialization efforts. With a strong balance sheet and a robust distribution partnership with BioHorizons, Orthocell is well-positioned to capitalize on the estimated US$735 million global market opportunity for Striate+, targeting a 20% market share.

Orthocell Secures US FDA Clearance for Remplir Nerve Repair Product
Apr 3, 2025

Orthocell Limited announced the US FDA 510(k) clearance for its Remplir nerve repair product, marking a significant milestone for the company. This clearance is expected to enhance Orthocell’s market positioning in regenerative medicine, potentially benefiting stakeholders by expanding the product’s availability and application in the US market.

Orthocell Secures FDA Clearance for Remplir, Targets US Nerve Repair Market
Apr 3, 2025

Orthocell Ltd has received US FDA 510(k) clearance for its nerve repair product, Remplir, allowing it to enter the US$1.6 billion US nerve repair market. This regulatory milestone is expected to significantly boost the company’s revenue and drive it towards profitability. Orthocell has prepared for this expansion with established logistics and sales pathways, a manufacturing facility capable of producing 100,000 units annually, and a strong cash reserve to support its US rollout and further market growth. The company aims to capture a meaningful market share without needing to displace existing dominant products, leveraging its proprietary manufacturing technology and strategic US commercial strategy.

Orthocell Limited Requests Trading Halt Pending FDA Clearance Announcement
Apr 2, 2025

Orthocell Limited has requested a trading halt on its securities pending an announcement regarding the results of its US FDA 510(k) clearance application. This clearance is crucial for the company as it seeks to commence commercial distribution in the US market, potentially impacting its market positioning and stakeholder interests.

Orthocell to Present at HealthInvest 2025, Updates on FDA Application
Apr 2, 2025

Orthocell Limited announced that its CEO, Paul Anderson, will present at the HealthInvest 2025 conference in Sydney, highlighting the company’s progress and strategic initiatives. The presentation will include an update on the US FDA application for the Remplir nerve repair product, which signifies a critical step in Orthocell’s expansion efforts and could enhance its market positioning in regenerative medicine.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025